Economic evaluation has been defined as `the comparative analysis of alternative courses of action in terms of both their costs and consequences’. In an economic evaluation in healthcare, two or more interventions are compared in terms of costs and health outcomes. This results in estimates of the incremental health effects and the incremental costs. If one intervention leads to higher costs as well as more health benefits, an incremental costeffectiveness ratio (ICER) can be calculated. This ratio expresses the cost per additional unit of health gain. An economic evaluation can play a role in policy makers’ decisions on whether the health benefits of an intervention are worth the costs.

Additional Metadata
Keywords COPD, health care costs
Promotor M.P.M.H. Rutten-van Mölken (Maureen) , O.C.P. Schayck (Onno)
Publisher Erasmus University Rotterdam
Sponsor The GO AHEAD trial (chapters 3, 4 and 5) was funded by from the Netherlands Organisation for Health Research and Development (ZonMw), grant numbers 945-50-773 and 945-07- 7309, and health insurers VGZ and CZ. The studies on quality-of life measurement and database research in COPD (chapters 6 and 10) were funded by Boehringer Ingelheim GmbH. The study on statistical methods in observational cost-effectiveness analysis (chapters 8 and 9) was funded by the Netherlands Organisation for Health Research and Development (ZonMW), grant number 152002017.
ISBN 978-94-6169-338-9
Persistent URL hdl.handle.net/1765/39439
Citation
Goossens, L.M.A. (2013, January 18). Underestimated uncertainties. Hospital-at-home for COPD exacerbations and methodological issues in the economic evaluation of healthcare. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/39439